Market Assessment
Oramed Pharmaceuticals (ORMP) is an Israeli small-cap ($54M) biopharma developing orally ingestible therapeutics for type 2 diabetes and weight management. ORMD-0801 is the lead and a Phase 2b investigative oral insulin capsule in clinical evaluation for type 2 diabetes. This article focuses on ORMD-0901.
Glucagon-like peptide (GLP.)-1 is derived from proglucagon, via proteolytic processing resulting in a biologically active form consisting of 30 amino acids. As a gut hormone, GLP-1 is secreted by the endocrine cells located in the epithelium of the small intestine cells in response to a meal